Is Dasatinib an imported drug?

Domestic drugs imported from overseas are classified as imported drugs. The original drug Dasatinib (Dasatinib) was first developed overseas by Bristol-Myers Squibb, and then entered the domestic drug market and was sold under the trade name Sprycel/Shidasai. Therefore, dasati that enters the country from overseas and is sold under this name is an imported drug.

Dasatinib is a prescription medicine indicated for the treatment of adults with newly diagnosed chronic phase (CP) Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) and adults with Ph+ CML who no longer benefit from or are intolerant to other treatments, including imatinib, and adults with Ph+ acute lymphoblastic leukemia (Ph+ ALL) who no longer benefit from or are intolerant to other treatments. Dasatinib can also be used to treat children 1 year and older with chronic phase Ph+ CML, and children 1 year and older with newly diagnosed Ph+ ALL who are receiving chemotherapy. It is not known whether dasatinib is safe and effective in children younger than 1 year old.

The original drug of dasatinib has been included in the scope of medical insurance after it was launched in China. Reimbursement is only available to eligible patients. Common specifications The price of each box of 50mg*60 tablets may be around 10,000 yuan. The price of the original drug overseas is even more expensive. Dasatinib generics are also sold overseas. The ingredients of the drug are basically the same as those sold domestically and abroad, but the price is cheap. For example, the price of a box of 50mg*60 tablets produced by an Indian pharmaceutical factory may be several hundred yuan (the price may fluctuate due to exchange rates).